A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma

Tejaswi V. Mudigonda, Kenneth Wyman, David R. Spigel, Kimberly B. Dahlman, F. Anthony Greco, Igor Puzanov, Mark C. Kelley, John D. Hainsworth, Jeffrey A. Sosman, Douglas B. Johnson*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations
Original languageEnglish (US)
Pages (from-to)101-103
Number of pages3
JournalPigment Cell and Melanoma Research
Volume29
Issue number1
DOIs
StatePublished - Jan 1 2016

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology
  • Dermatology
  • Oncology

Cite this